Printer Friendly

Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study.

Summary: Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog

Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)

JERUSALEM, October 20/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.(OTCBB: ORMP.OB; http://www.oramed.com), a developer of oral drug delivery systems, announced today that its poster entitled "A novel GLP-1 analog delivered orally reduces postprandial glucose excursions in a porcine model," has been accepted for presentation at the Diabetes Technology Society's Ninth Annual Meeting in San Francisco, California between November 5-7, 2009.

"The selection of Oramed as one of the companies to present at theDiabetes Technology Conference is a wonderful opportunity for us todemonstrate our technology to the world's leading diabetes scientists," saidNadav Kidron, Oramed CEO.

Oramed's abstract will be presented on Thursday November 5, 2009, at 5:30PM. The poster will be available for viewing throughout the conference.

For more information about the Diabetes Technology Society's Ninth AnnualMeeting, please visit http://www.diabetestechnology.org/

For more information about Oramed Pharmaceuticals, please visithttp://www.oramed.com

2009 Al Bawaba (www.albawaba.com)

2009 Al Bawaba (Albawaba.com)

Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2009 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Albawaba.com
Date:Oct 20, 2009
Words:205
Previous Article:Abbas in Cairo as Hamas rejects disarming military wing.
Next Article:BluePhoenix Rehosting Solution Enables Volvofinans to Reduce TCO of Credit Card System by 40%,.
Topics:


Related Articles
BIOCRYST COMPLETES BCX-4208 PHASE I TRIAL FOR PSORIASIS.
Once-daily liraglutide lowers Hb[A.sub.1c] by 1.7% in early trial.
New drug class for diabetes looks promising: dipeptidyl peptidase 4 inhibitors give good control and cause few side effects.
Anadys Initiates Phase I Clinical Trial of Non-Nucleoside Polymerase Inhibitor for Treatment of Hepatitis C.
ELIGEN WITH GLP-1 AND PYY3-36 SUPPRESSES APPETITE.
ORAMED AWARDED NIS 3.1 MILLION GRANT FROM ISRAEL.

Terms of use | Copyright © 2015 Farlex, Inc. | Feedback | For webmasters